bioAffinity Technologies (NASDAQ:BIAF) Stock Scheduled to Reverse Split on Monday, August 24th

Shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) are set to reverse split before the market opens on Monday, August 24th. The 1-15 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, August 23rd.

bioAffinity Technologies Price Performance

bioAffinity Technologies stock traded down $0.01 during midday trading on Thursday, reaching $0.40. The stock had a trading volume of 3,329,193 shares, compared to its average volume of 9,021,737. The firm’s fifty day simple moving average is $0.71 and its 200-day simple moving average is $1.59. The company has a quick ratio of 1.41, a current ratio of 1.44 and a debt-to-equity ratio of 0.14. bioAffinity Technologies has a 1-year low of $0.33 and a 1-year high of $13.50.

bioAffinity Technologies (NASDAQ:BIAF) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.10) by $1.46. The firm had revenue of $1.51 million during the quarter, compared to the consensus estimate of $1.70 million. bioAffinity Technologies had a negative return on equity of 220.52% and a negative net margin of 257.30%.

Analysts Set New Price Targets

Several research analysts recently commented on BIAF shares. Wall Street Zen upgraded shares of bioAffinity Technologies from a “sell” rating to a “hold” rating in a report on Monday, August 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Monday, July 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, bioAffinity Technologies has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. J. Safra Sarasin Holding AG acquired a new stake in shares of bioAffinity Technologies in the 1st quarter valued at approximately $164,000. Scientech Research LLC bought a new position in shares of bioAffinity Technologies in the third quarter valued at $49,000. Finally, Geode Capital Management LLC bought a new stake in bioAffinity Technologies during the fourth quarter worth $36,000. Institutional investors and hedge funds own 1.64% of the company’s stock.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.